InVision Medical Technology vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-09
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionInVision Medical TechnologyIsomorphic Labs
PricingContact sales (enterprise)Contact sales (pharma partnerships)
Primary ApplicationAI for echocardiography (LVEF, cardiac amyloid)AI for drug discovery (AlphaFold-based)
Regulatory ValidityFDA 510(k) clearance, CPT code, peer-reviewedPre-clinical R&D, no regulatory submissions
Deployment ModelDICOM-native, PACS/EHR integrated, post-processingAI drug design engine via collaborations
Target CustomerHealth systems, cardiology departmentsLarge pharma companies
InVision Medical Technology
InVision Medical Technology

FDA-cleared echo AI that automates LVEF, flags cardiac amyloidosis, and bills under CPT 0932T plus a 2026 Medicare NTAP.

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
10 views
7.5k views
Skill Level
Intermediate
Advanced
API Available
Platforms
WebAPI
—
Categories
🏥 Healthcare
🧬 Drug Discovery & Life Sciences
Features
Precision LVEF: automated left ventricular ejection fraction from standard echo DICOM
Precision LVEF reported 4.1% mean absolute error predicting EF in external validation
Blinded randomized trial (Nature, He et al. 2023) across 3,495 transthoracic echocardiograms
16.8% of AI studies substantially changed by cardiologists vs 27.2% for sonographers
Precision Cardiac Amyloid: detection from apical-4-chamber and parasternal-long-axis views
Developed with Alexion, AstraZeneca Rare Disease
FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
Precision Cardiac Amyloid holds FDA Breakthrough Device designation and TAP enrollment
Vendor-neutral DICOM input from GE, Philips, Siemens, Canon, and handheld POCUS
DICOM-native post-processing; runs alongside PACS, CVIS, and Epic EHR
No new hardware, no new views, no acquisition change required
Typical four-week implementation from kick-off to go-live
On-premise or validated cloud deployment with PHI staying in your network on-premise
US-only data residency; SOC 2, ISO 13485, and HIPAA aligned
Precision Reporting (in development): 18 B-mode and Doppler parameters with draft wording on EchoPrime and EchoNet-Measurements
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Builds on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Series B investment round announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Interdisciplinary team of drug discovery experts and ML specialists
Founded by Demis Hassabis, who serves as CEO
Integrations
Epic
PACS
CVIS

Who should pick which

  • Health system CMO
    Pick: InVision Medical Technology

    InVision provides FDA-cleared, CPT-billable AI that integrates with existing PACS and EHR, reducing sonographer time and improving diagnostic consistency.

  • Chief of Cardiology
    Pick: InVision Medical Technology

    Standardize LVEF measurements across multiple sites and screen for undiagnosed cardiac amyloidosis without new hardware.

  • Big Pharma R&D head
    Pick: Isomorphic Labs

    Isomorphic Labs offers AlphaFold-based drug design engine and predictive models, suited for large-scale lead optimization and novel molecule generation via partnership.

  • Independent echocardiography lab
    Pick: InVision Medical Technology

    Even for smaller groups, InVision's DICOM-native post-processing can improve turnaround and measurement reproducibility, though enterprise procurement may be required.

  • Academic research lab (drug discovery)
    Pick: Isomorphic Labs

    Isomorphic Labs collaborates with large pharma, not individual labs; not accessible for independent researchers.

Frequently Asked Questions

Is InVision Medical Technology FDA approved?

Yes, InVision has FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid.

Does Isomorphic Labs have any FDA-cleared products?

No, Isomorphic Labs is a pre-clinical drug discovery AI company with no FDA-cleared products.

Can I try InVision Medical Technology for free?

No, InVision requires contacting sales for enterprise pricing; no self-service or free trial available.

How does Isomorphic Labs price its AI?

Isomorphic Labs operates through pharma partnerships with undisclosed deal values; no per-use or subscription pricing.

What integrations does InVision support?

InVision integrates with PACS, Epic EHR, and structured reporting platforms, processing standard DICOM studies.

Is Isomorphic Labs available as a software product?

No, Isomorphic Labs is not a standalone product; it partners with pharma companies for collaborative drug discovery.

Does InVision have published clinical validation?

Yes, InVision's algorithms have been published in Nature, Nature Medicine, JAMA Cardiology, and NEJM AI.

What recent funding has Isomorphic Labs raised?

Isomorphic Labs announced a $600M external investment round in 2025 and a Series B in February 2026 (amount undisclosed).

More InVision Medical Technology or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026